Physician profile
Juan Ling
NPI 1326068040
$1,801.62
in general payments reported to CMS, 2019-2025
21 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $125 · 2021: $165 · 2022: $58.31 · 2023: $397 · 2024: $287 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $261.65 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Exact Sciences Corporation | $244.28 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $219.39 | 2023-2025 | Veozah |
| Janssen Biotech, INC. | $156.77 | 2021-2023 | Tremfya |
| Vyne Pharmaceuticals INC. | $124.99 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $124.02 | 2021 | |
| Depuy Synthes Sales INC. | $119.93 | 2019 | |
| Boston Scientific Corporation | $113.93 | 2019 | |
| Abbvie INC. | $97.08 | 2022-2025 | |
| Covidien LP | $58.14 | 2019 | |
| Lilly USA, LLC | $54.55 | 2022-2023 | Mounjaro |
| Gilead Sciences, INC. | $44.60 | 2025 | |
| Leo Pharma INC. | $25.96 | 2023 | Adbry |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $25.49 | 2025 | |
| Dermira, INC. | $24.50 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $23.16 | 2025 | Veregen |
| Novo Nordisk INC | $19.28 | 2024 | Rybelsus, Ozempic |
| Sun Pharmaceutical Industries INC. | $18.81 | 2023 | Absorica Ld, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.89 | 2019 | |
| Amgen INC. | $15.08 | 2025 | Evenity |
| Almirall LLC | $14.12 | 2023 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.